Trials / Completed
CompletedNCT01604746
Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801
Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,146 (actual)
- Sponsor
- Alachua Government Services, Inc. · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to verify the long-term safety of a 2.5 µg, adjuvanted (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ross River Virus (RRV) Vaccine | Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study. |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2012-05-24
- Last updated
- 2015-10-09
Locations
13 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT01604746. Inclusion in this directory is not an endorsement.